Akari Therapeutics annual r&d spending
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Akari Therapeutics R&D Spending Growth & History (AKTX)
Akari Therapeutics's r&d spending was $2.8M for fiscal 2025.
View full Akari Therapeutics company overviewAkari Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.8M | −$4.2M | −59.69% |
| 2024 | 2024-12-31 | $7.0M | $1.5M | +28.13% |
| 2023 | 2023-12-31 | $5.5M | −$4.1M | −43.00% |
| 2022 | 2022-12-31 | $9.6M | $427,545 | +4.68% |
| 2021 | 2021-12-31 | $9.1M | $313,251 | +3.55% |
| 2020 | 2020-12-31 | $8.8M | $80,784 | +0.92% |
| 2019 | 2019-12-31 | $8.7M | −$3.1M | −25.91% |
| 2018 | 2018-12-31 | $11.8M | −$11.5M | −49.34% |
| 2017 | 2017-12-31 | $23.3M | $6.0M | +34.55% |
| 2016 | 2016-12-31 | $17.3M | $11.5M | +198.43% |
| 2015 | 2015-12-31 | $5.8M | $4.2M | +258.81% |
| 2014 | 2014-12-31 | $1.6M | $340,204 | +26.66% |
| 2013 | 2013-12-31 | $1.3M | −$207,000 | −13.96% |
| 2012 | 2012-12-31 | $1.5M | $642,000 | +76.34% |
| 2011 | 2011-12-31 | $841,000 | $594,000 | +240.49% |
| 2010 | 2010-12-31 | $247,000 | — | — |
Akari Therapeutics quarterly r&d spending
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.1M | $1.4M | +211.39% |
| Q1 2026 | 2026-03-31 | $1.5M | $646,000 | +79.46% |
| Q4 2025 | 2025-12-31 | $1.1M | −$161,000 | −12.91% |
| Q3 2025 | 2025-09-30 | $249,000 | $106,000 | +74.13% |
| Q2 2025 | 2025-06-30 | $667,000 | −$2.6M | −79.87% |
| Q1 2025 | 2025-03-31 | $813,000 | −$1.5M | −64.33% |
| Q4 2024 | 2024-12-31 | $1.2M | −$634,000 | −33.71% |
| Q3 2024 | 2024-09-30 | $143,000 | −$171,000 | −54.46% |
| Q2 2024 | 2024-06-30 | $3.3M | $1.8M | +117.45% |
| Q1 2024 | 2024-03-31 | $2.3M | $548,000 | +31.66% |
| Q4 2023 | 2023-12-31 | $1.9M | — | — |
| Q3 2023 | 2023-09-30 | $314,000 | — | — |
| Q2 2023 | 2023-06-30 | $1.5M | −$1.3M | −46.55% |
| Q1 2023 | 2023-03-31 | $1.7M | — | — |
| Q2 2022 | 2022-06-30 | $2.9M | $667,759 | +30.58% |
| Q2 2021 | 2021-06-30 | $2.2M | −$837,083 | −27.71% |
| Q2 2020 | 2020-06-30 | $3.0M | −$572,909 | −15.94% |
| Q2 2019 | 2019-06-30 | $3.6M | −$1.5M | −29.83% |
| Q2 2018 | 2018-06-30 | $5.1M | $1.3M | +35.39% |
| Q2 2017 | 2017-06-30 | $3.8M | −$1.7M | −30.51% |
| Q2 2016 | 2016-06-30 | $5.4M | $4.4M | +443.67% |
| Q1 2016 | 2016-03-31 | $1.5M | −$55,407 | −3.56% |
| Q4 2015 | 2015-12-31 | $1.9M | — | — |
| Q3 2015 | 2015-09-30 | $1.3M | $1.2M | +707.79% |
| Q2 2015 | 2015-06-30 | $1.0M | −$538,820 | −34.99% |
| Q1 2015 | 2015-03-31 | $1.6M | $754,950 | +94.37% |
| Q3 2014 | 2014-09-30 | $162,575 | — | — |
| Q2 2014 | 2014-06-30 | $1.5M | — | — |
| Q1 2014 | 2014-03-31 | $800,000 | — | — |
Akari Therapeutics r&d spending trends
Over the last five fiscal years, Akari Therapeutics's r&d spending decreased from $8.8M to $2.8M, a change of −$6.0M. The latest reported quarter, Q2 2026, shows $2.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akari Therapeutics source filings ↗